The European Medicines Agency (EMA) is set to host a series of interactive Q&A sessions focused on the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service. These sessions aim to provide comprehensive support and clarity to stakeholders navigating the regulatory data management landscape.
Details of the Upcoming Q&A Session
Scheduled for Thursday, September 18, 2025, from 14:00 to 15:00 Amsterdam time (CEST), the session will be conducted online, allowing participants from various regions to join seamlessly. The EMA’s regulatory data management team will be on hand to address queries related to the XEVMPD service, ensuring that users can effectively utilize the platform for their medicinal product registrations and monitoring.
Ongoing Support Through Monthly Clinics
Following the initial event in September, the EMA will continue to offer monthly Q&A clinics until the end of 2025. These recurring sessions will cover a range of topics, including Substance, Organisation, Referentials Management Services, and SPOR master data. Additionally, dedicated clinics for these areas will provide specialized assistance, catering to the diverse needs of the pharmaceutical community.
• Participants gain direct access to EMA experts
• Enhanced understanding of XEVMPD functionalities
• Continuous updates and best practices shared monthly
This structured approach ensures that stakeholders remain well-informed and supported throughout their engagement with the EMA’s regulatory frameworks. By offering timely and relevant information, the EMA reinforces its commitment to facilitating the efficient and safe management of medicinal products within the European market.
Access to these sessions is straightforward, with registration currently open on the EMA’s official website. Recorded videos of the events will be made available post-session, providing an invaluable resource for those unable to attend live. This initiative underscores the EMA’s dedication to transparency and continuous improvement in regulatory practices.
Engaging directly with the regulatory team allows for real-time problem-solving and clarification of complex procedures, fostering a more collaborative environment between the EMA and its stakeholders. This proactive support mechanism not only streamlines the regulatory process but also enhances the overall quality and safety standards of medicinal products in the EU.
Stakeholders and industry professionals are encouraged to take advantage of these sessions to stay updated on the latest regulatory developments and to ensure compliance with the evolving standards set by the EMA.
The EMA’s initiative to host regular Q&A clinics exemplifies a forward-thinking approach to regulatory support, recognizing the dynamic nature of the pharmaceutical sector. By prioritizing accessibility and continuous learning, the agency strengthens its role as a pivotal resource for medicinal product regulation, ultimately contributing to public health and safety across Europe.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
